Sterile product facility design and project management, second edition

Sterile Product Facility Design and Project Management, Second Edition

Volumn , Issue , 2004, Pages 1-374

  Odum, Jeffery N ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057500148     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (38)

1. Construction Industry Institute. 1994. Pre-project planning: Beginning a project the right way. No. 39-1 (May).
2. Skibo, A. 1989. Project management and contracting issues, Part 1: Project team development. Biopharm (April).
3. Pena, W. 1987. Problem seeking. Washington, DC: AIA Press.
4. Diekmann, J., and K. B. Thrush. 1990. A report to the Construction Industry Institute: Cost and schedule controls. Boulder: University of Colorado.
5. Code of Federal Regulations, Title 21, Part 211.42. 1990. Washington, DC: U.S. Government Printing Office.
6. Code of Federal Regulations, Title 21, Part 211.42. 1990. Washington, DC: U.S. Government Printing Office.
7. Code of Federal Regulations, Title 21, Part 211.46. 1990. Washington, DC: U.S. Government Printing Office.
8. FDA. 2000. Q7A Good manufacturing practice guide for active pharmaceutical ingredients. Guidance for Industry (November).
9. Weiss, M. 1992. Ongoing issues in the management and operation of biotech cleanrooms. Genetic Engineering News (November).
10. Code of Federal Regulations, Title 21, Part 211.42. 1990. Washington, DC: U.S. Government Printing Office.
11. The ISPE Commissioning and Qualification (C&Q) Baseline Guide.
12. The FDA has indicated that it will have an expectation for design qualifications to be performed on API (and bulk biotech) facilities.
13. American Heritage Dictionary, 2nd college edition. 1985. Boston: Houghton Mifflin Company.
14. Code of Federal Regulations, Title 21, Part 211.42. 1990. Washington, DC: U.S. Government Printing Office.
15. Guidelines for research involving recombinant DNA molecules. 1994. Washington, DC: Centers for Disease Control and National Institutes of Health.
16. Guideline for the inspection of biotechnology manufacturing facilities. 1991. Rockville, MD: Food and Drug Administration, Division of Field Investigations (HFC-130).
17. PMA white paper on multiuse manufacturing facilities for biologicals. 1992. Washington, DC: Pharmaceutical Manufacturers’ Association.
18. Code of Federal Regulations, Title 21, Parts 600–680. 1992. Washington, DC: U.S. Government Printing Office.
19. Code of Federal Regulations, Title 21, Part 211.42. 1990. Washington, DC: U.S. Government Printing Office.
20. Food and Drug Administration. 1985. Points to consider in the production and testing of new drugs and biologicals produced by DNA technology. Rockville, MD: FDA Congressional and Consumer and International Affairs Staff.
21. Food and Drug Administration. 1987. Points to consider in the manufacture and testing of monoclonal antibody products for human use. Rockville, MD: FDA Congressional Consumer and International Affairs Staff.
22. Food and Drug Administration. 1987. Points to consider in the characterization of cell lines used to produce biologicals. Rockville, MD: FDA Congressional Consumer and International Affairs Staff.
23. National Institutes of Health. 1986. Guidelines for research involving recombinant DNA molecules. Washington, DC: U.S. Government Printing Office.
24. PMA white paper on multiuse manufacturing facilities for biologicals. 1992. Washington, DC: Pharmaceutical Manufacturers’ Association.
25. PMA white paper on multiuse manufacturing facilities for biologicals. 1992. Washington, DC: Pharmaceutical Manufacturers’ Association.
26. PMA white paper on multiuse manufacturing facilities for biologicals. 1992. Washington, DC: Pharmaceutical Manufacturers’ Association.
27. Federal Standard 209E, Cleanroom and Work Station, Controlled Environments. 1992. Washington, DC: General Services Administration.
28. PMA white paper on multiuse manufacturing facilities for biologicals. 1992. Washington, DC: Pharmaceutical Manufacturers’ Association.
29. Code of Federal Regulations, Title 21, Part 211.28. 1990. Washington, DC: U.S. Government Printing Office.
30. PMA white paper on multiuse manufacturing facilities for biologicals. 1992. Washington, DC: Pharmaceutical Manufacturers’ Association.
31. Guideline for the inspection of biotechnology manufacturing facilities. 1991. Rockville, MD: Food and Drug Administration. Division of Field Investigations (HFC-130).
32. PMA white paper on multiuse manufacturing facilities for biologicals. 1992. Washington, DC: Pharmaceutical Manufacturers’ Association.
33. Perez, M. 1977. Human safety data collection and evaluation for the approval of new animal drugs. Journal of Toxicology and Environmental Health 3.
34. Cleaning validation. 1992. Mid-Atlantic region inspection guide. Rockville, MD: Food and Drug Administration.
35. Hardec, S. W. 1984. The validation of cleaning procedures. Pharmaceutical Technology 8 (5).
36. American Institute of Architects, 1735 New York Avenue NW, Washington, DC 20006.
37. DeBenedictis, D., and R. McLeod. Construction contracts. In Handbook of construction management, p. 48. New York: Van Nostrand Reinhold.
38. Burrill & Company. 2003. Biotech 2003.